{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:44:19Z","timestamp":1790747059584,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,6,22]],"date-time":"2010-06-22T00:00:00Z","timestamp":1277164800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2010,6,22]],"date-time":"2010-06-22T00:00:00Z","timestamp":1277164800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Autoantibodies against mutated and citrullinated vimentin (MCV) represent a novel diagnostic marker for rheumatoid arthritis (RA). Recently, an increased sensitivity for anti-MCV compared to autoantibodies against cyclic citrullinated peptides (anti-CCP2) was shown in cohorts of patients with early RA and established disease.<\/jats:p>\n                    <jats:p>The aim of this study was to develop and evaluate a point of care test (POCT) for detection of anti-MCV antibodies immediately at the first visit or at the bed side.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A lateral-flow immunoassay was developed for simultaneous detection of anti-MCV antibodies and rheumatoid factor (RF-IgG) and evaluated in a prospective setting. Analyses were performed from whole blood samples of patients with seropositive RA (n = 108), seronegative RA as well as other rheumatic disorders (n = 122), and healthy blood donors (n = 200) and compared to detection via ELISA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Using the POCT, anti-MCV antibodies were detected in 54.6% and RF-IgG in 56.5% of patients with RA. Specificity was 99.1% for anti-MCV antibodies and 91.2% for RF-IgG. Compared to ELISA's results, POCT sensitivity was 69.3% for anti-MCV and 55.6% for RF-IgG, specificity was 99.7% and 97.2%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This POCT for detection of anti-MCV antibodies and RF-IgG provides high specificity for the diagnosis of RA and is useful in clinical practice due to its simplicity and its reliable performance. This test can greatly improve a timely management of RA and may help in screening patients with suspected RA in non-specialized settings prompting early referrals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/ar3057","type":"journal-article","created":{"date-parts":[[2010,8,25]],"date-time":"2010-08-25T05:34:30Z","timestamp":1282714470000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Immediate determination of ACPA and rheumatoid factor - a novel point of care test for detection of anti-MCV antibodies and rheumatoid factor using a lateral-flow immunoassay"],"prefix":"10.1186","volume":"12","author":[{"given":"Franziska","family":"Renger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Feist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"Fredenhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Natusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Backhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd-R","family":"Burmester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Egerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,6,22]]},"reference":[{"key":"2892_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/rheumatology\/39.1.28","volume":"39","author":"NJ Cooper","year":"2000","unstructured":"Cooper NJ: Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford). 2000, 39: 28-33. 10.1093\/rheumatology\/39.1.28.","journal-title":"Rheumatology (Oxford)"},{"key":"2892_CR2","first-page":"481","volume":"34","author":"K Eberhardt","year":"2007","unstructured":"Eberhardt K, Larsson BM, Nived K, Lindqvist E: Work disability in rheumatoid arthritis--development over 15 years and evaluation of predictive factors over time. J Rheumatol. 2007, 34: 481-487.","journal-title":"J Rheumatol"},{"key":"2892_CR3","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1002\/art.22817","volume":"56","author":"H Bang","year":"2007","unstructured":"Bang H, Egerer K, Gauliard A, Luthke K, Rudolph PE, Fredenhagen G, Berg W, Feist E, Burmester GR: Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum. 2007, 56: 2503-2511. 10.1002\/art.22817.","journal-title":"Arthritis Rheum"},{"key":"2892_CR4","doi-asserted-by":"publisher","first-page":"R119","DOI":"10.1186\/ar2008","volume":"8","author":"C Dejaco","year":"2006","unstructured":"Dejaco C, Klotz W, Larcher H, Duftner C, Schirmer M, Herold M: Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther. 2006, 8: R119-10.1186\/ar2008.","journal-title":"Arthritis Res Ther"},{"key":"2892_CR5","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1373\/clinchem.2006.078063","volume":"53","author":"D Coenen","year":"2007","unstructured":"Coenen D, Verschueren P, Westhovens R, Bossuyt X: Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein\/peptide antibodies in the diagnosis of rheumatoid arthritis. Clin Chem. 2007, 53: 498-504. 10.1373\/clinchem.2006.078063.","journal-title":"Clin Chem"},{"key":"2892_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/art.23188","volume":"58","author":"L Mathsson","year":"2008","unstructured":"Mathsson L, Mullazehi M, Wick MC, Sjoberg O, van Vollenhoven R, Klareskog L, Ronnelid J: Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum. 2008, 58: 36-45. 10.1002\/art.23188.","journal-title":"Arthritis Rheum"},{"key":"2892_CR7","first-page":"1658","volume":"34","author":"L Soos","year":"2007","unstructured":"Soos L, Szekanecz Z, Szabo Z, Fekete A, Zeher M, Horvath IF, Danko K, Kapitany A, Vegvari A, Sipka S, Szegedi G, Lakos G: Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis. J Rheumatol. 2007, 34: 1658-1663.","journal-title":"J Rheumatol"},{"key":"2892_CR8","first-page":"1002","volume":"35","author":"L Innala","year":"2008","unstructured":"Innala L, Kokkonen H, Eriksson C, Jidell E, Berglin E, Dahlqvst SR: Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol. 2008, 35: 1002-1008.","journal-title":"J Rheumatol"},{"key":"2892_CR9","doi-asserted-by":"publisher","first-page":"R142","DOI":"10.1186\/ar2570","volume":"10","author":"P Nicaise Roland","year":"2008","unstructured":"Nicaise Roland P, Grootenboer Mignot S, Bruns A, Hurtado M, Palazzo E, Hayem G, Dieude P, Meyer O, Chollet Martin S: Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy. Arthritis Res Ther. 2008, 10: R142-10.1186\/ar2570.","journal-title":"Arthritis Res Ther"},{"key":"2892_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s12016-007-8016-3","volume":"34","author":"H Poulsom","year":"2008","unstructured":"Poulsom H, Charles PJ: Antibodies to citrullinated vimentin are a specific and sensitive marker for the diagnosis of rheumatoid arthritis. Clin Rev Allergy Immunol. 2008, 34: 4-10. 10.1007\/s12016-007-8016-3.","journal-title":"Clin Rev Allergy Immunol"},{"key":"2892_CR11","doi-asserted-by":"publisher","first-page":"R12","DOI":"10.1186\/ar2362","volume":"10","author":"J Ursum","year":"2008","unstructured":"Ursum J, Nielen MM, van Schaardenburg D, van der Horst AR, van de Stadt RJ, Dijkmans BA, Hamann D: Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study. Arthritis Res Ther. 2008, 10: R12-10.1186\/ar2362.","journal-title":"Arthritis Res Ther"},{"key":"2892_CR12","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s00296-009-0854-2","volume":"29","author":"E Wagner","year":"2009","unstructured":"Wagner E, Skoumal M, Bayer PM, Klaushofer K: Antibody against mutated citrullinated vimentin: a new sensitive marker in the diagnosis of rheumatoid arthritis. Rheumatol Int. 2009, 29: 1315-1321. 10.1007\/s00296-009-0854-2.","journal-title":"Rheumatol Int"},{"key":"2892_CR13","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/art.1780370606","volume":"37","author":"KW Chan","year":"1994","unstructured":"Chan KW, Felson DT, Yood RA, Walker AM: The lag time between onset of symptoms and diagnosis of rheumatoid arthritis. Arthritis Rheum. 1994, 37: 814-820. 10.1002\/art.1780370606.","journal-title":"Arthritis Rheum"},{"key":"2892_CR14","first-page":"2323","volume":"27","author":"C Hernandez-Garcia","year":"2000","unstructured":"Hernandez-Garcia C, Vargas E, Abasolo L, Lajas C, Bellajdell B, Morado IC, Macarron P, Pato E, Fernandez-Gutierrez B, Banares A, Jover JA: Lag time between onset of symptoms and access to rheumatology care and DMARD therapy in a cohort of patients with rheumatoid arthritis. J Rheumatol. 2000, 27: 2323-2328.","journal-title":"J Rheumatol"},{"key":"2892_CR15","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/03009740701867331","volume":"37","author":"GF Snijders","year":"2008","unstructured":"Snijders GF, Broeder AA, Bevers K, Jeurissen ME, van Eerd JE, van den Hoogen FH: Measurement characteristics of a new rapid anti-CCP2 test compared to the anti-CCP2 ELISA. Scand J Rheumatol. 2008, 37: 151-154. 10.1080\/03009740701867331.","journal-title":"Scand J Rheumatol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar3057.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/ar3057\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar3057.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T07:01:47Z","timestamp":1728370907000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/ar3057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,22]]},"references-count":15,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2010,6]]}},"alternative-id":["2892"],"URL":"https:\/\/doi.org\/10.1186\/ar3057","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,22]]},"assertion":[{"value":"21 January 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2010","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2010","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2010","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R120"}}